Quelles sont les conséquences d'une inhibition des MAP kinases ?
L'inhibition peut entraîner des effets indésirables comme une immunosuppression ou des troubles de la croissance.
InhibitionImmunosuppression
Facteurs de risque
5
#1
Quels facteurs de risque sont associés aux troubles des MAP kinases ?
Des facteurs incluent des prédispositions génétiques, l'exposition à des toxines et le stress.
Facteurs de risquePrédispositions génétiques
#2
Le mode de vie influence-t-il les risques liés aux MAP kinases ?
Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques.
Mode de vieAlimentation
#3
L'âge est-il un facteur de risque pour les troubles des MAP kinases ?
Oui, le vieillissement peut affecter la signalisation des MAP kinases et augmenter les risques.
ÂgeVieillissement
#4
Les infections peuvent-elles influencer les MAP kinases ?
Certaines infections peuvent activer les MAP kinases, contribuant à des maladies inflammatoires.
InfectionsMaladies inflammatoires
#5
Le tabagisme est-il un facteur de risque pour les troubles des MAP kinases ?
Oui, le tabagisme peut altérer la signalisation des MAP kinases et augmenter le risque de cancer.
TabagismeCancer
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Système de signalisation des MAP kinases : Questions médicales les plus fréquentes",
"headline": "Système de signalisation des MAP kinases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Système de signalisation des MAP kinases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-26",
"dateModified": "2025-04-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Système de signalisation des MAP kinases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Transduction du signal",
"url": "https://questionsmedicales.fr/mesh/D015398",
"about": {
"@type": "MedicalCondition",
"name": "Transduction du signal",
"code": {
"@type": "MedicalCode",
"code": "D015398",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G04.835"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Système de signalisation des MAP kinases",
"alternateName": "MAP Kinase Signaling System",
"code": {
"@type": "MedicalCode",
"code": "D020935",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "David S Waddell",
"url": "https://questionsmedicales.fr/author/David%20S%20Waddell",
"affiliation": {
"@type": "Organization",
"name": "University of North Florida, Department of Biology, 1 UNF Drive, Jacksonville, FL 32224, USA. Electronic address: d.s.waddell@unf.edu."
}
},
{
"@type": "Person",
"name": "Yuelin Zhang",
"url": "https://questionsmedicales.fr/author/Yuelin%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Botany, University of British Columbia, Vancouver, BC, Canada."
}
},
{
"@type": "Person",
"name": "Emmanuel Prikas",
"url": "https://questionsmedicales.fr/author/Emmanuel%20Prikas",
"affiliation": {
"@type": "Organization",
"name": "Dementia Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia."
}
},
{
"@type": "Person",
"name": "Arne Ittner",
"url": "https://questionsmedicales.fr/author/Arne%20Ittner",
"affiliation": {
"@type": "Organization",
"name": "Dementia Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia."
}
},
{
"@type": "Person",
"name": "T S Keshava Prasad",
"url": "https://questionsmedicales.fr/author/T%20S%20Keshava%20Prasad",
"affiliation": {
"@type": "Organization",
"name": "Center for Systems Biology and Molecular Medicine, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, 575018, India. keshav@yenepoya.edu.in."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Classification of Local Recurrence After Nipple-Sparing Mastectomy Based on Location: The Features of Nipple-Areolar Recurrence Differ from Those of Other Local Recurrences.",
"datePublished": "2022-11-13",
"url": "https://questionsmedicales.fr/article/36371582",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1245/s10434-022-12760-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Feasibility of local therapy for recurrent pancreatic cancer.",
"datePublished": "2022-05-24",
"url": "https://questionsmedicales.fr/article/35641368",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.pan.2022.05.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ultrasound Assessment of Skin Tumors Local Recurrence.",
"datePublished": "2023-05-17",
"url": "https://questionsmedicales.fr/article/37195073",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jum.16255"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pathological determinants of outcome following resection of locally advanced or locally recurrent rectal cancer.",
"datePublished": "2023-06-26",
"url": "https://questionsmedicales.fr/article/37442715",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejso.2023.06.023"
}
},
{
"@type": "ScholarlyArticle",
"name": "Intraparenchymal metastases as a cause for local recurrence of pancreatic cancer.",
"datePublished": "2022-11-21",
"url": "https://questionsmedicales.fr/article/36371607",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/his.14839"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes physiologiques cellulaires",
"item": "https://questionsmedicales.fr/mesh/D002468"
},
{
"@type": "ListItem",
"position": 3,
"name": "Transduction du signal",
"item": "https://questionsmedicales.fr/mesh/D015398"
},
{
"@type": "ListItem",
"position": 4,
"name": "Système de signalisation des MAP kinases",
"item": "https://questionsmedicales.fr/mesh/D020935"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Système de signalisation des MAP kinases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Système de signalisation des MAP kinases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Système de signalisation des MAP kinases",
"description": "Comment diagnostiquer une dysrégulation des MAP kinases ?\nQuels tests sont utilisés pour évaluer les MAP kinases ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels marqueurs biologiques sont associés aux MAP kinases ?\nPeut-on utiliser l'imagerie pour diagnostiquer des troubles liés aux MAP kinases ?",
"url": "https://questionsmedicales.fr/mesh/D020935?mesh_terms=Neoplasm+Recurrence,+Local#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Système de signalisation des MAP kinases",
"description": "Quels symptômes indiquent une activation anormale des MAP kinases ?\nLes troubles neurologiques sont-ils liés aux MAP kinases ?\nComment les MAP kinases affectent-elles le cancer ?\nLes maladies auto-immunes sont-elles liées aux MAP kinases ?\nQuels signes cliniques sont associés à une inflammation chronique ?",
"url": "https://questionsmedicales.fr/mesh/D020935?mesh_terms=Neoplasm+Recurrence,+Local#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Système de signalisation des MAP kinases",
"description": "Peut-on prévenir les troubles liés aux MAP kinases ?\nLes examens réguliers aident-ils à prévenir les maladies liées aux MAP kinases ?\nL'évitement de certains médicaments peut-il prévenir des dysfonctionnements des MAP kinases ?\nComment le stress influence-t-il les MAP kinases ?\nLes vaccinations peuvent-elles influencer la signalisation des MAP kinases ?",
"url": "https://questionsmedicales.fr/mesh/D020935?mesh_terms=Neoplasm+Recurrence,+Local#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Système de signalisation des MAP kinases",
"description": "Quels traitements ciblent les MAP kinases dans le cancer ?\nLes thérapies géniques peuvent-elles corriger les anomalies des MAP kinases ?\nComment les anti-inflammatoires affectent-ils les MAP kinases ?\nLes traitements ciblés sont-ils efficaces contre les maladies liées aux MAP kinases ?\nQuels sont les effets secondaires des inhibiteurs de MAP kinases ?",
"url": "https://questionsmedicales.fr/mesh/D020935?mesh_terms=Neoplasm+Recurrence,+Local#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Système de signalisation des MAP kinases",
"description": "Quelles complications peuvent survenir avec une activation excessive des MAP kinases ?\nLes troubles cardiovasculaires sont-ils liés aux MAP kinases ?\nComment les MAP kinases sont-elles impliquées dans le diabète ?\nLes maladies neurodégénératives sont-elles liées aux MAP kinases ?\nQuelles sont les conséquences d'une inhibition des MAP kinases ?",
"url": "https://questionsmedicales.fr/mesh/D020935?mesh_terms=Neoplasm+Recurrence,+Local#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Système de signalisation des MAP kinases",
"description": "Quels facteurs de risque sont associés aux troubles des MAP kinases ?\nLe mode de vie influence-t-il les risques liés aux MAP kinases ?\nL'âge est-il un facteur de risque pour les troubles des MAP kinases ?\nLes infections peuvent-elles influencer les MAP kinases ?\nLe tabagisme est-il un facteur de risque pour les troubles des MAP kinases ?",
"url": "https://questionsmedicales.fr/mesh/D020935?mesh_terms=Neoplasm+Recurrence,+Local#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysrégulation des MAP kinases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de protéines peuvent aider à identifier des anomalies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer les MAP kinases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'immunoblotting et la cytométrie en flux pour mesurer l'activité."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles nécessaires pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des biopsies peuvent être nécessaires pour évaluer l'expression des MAP kinases."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés aux MAP kinases ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs comme ERK, JNK et p38 sont souvent analysés dans les études."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour diagnostiquer des troubles liés aux MAP kinases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie peut aider à visualiser des tumeurs, mais ne cible pas directement les MAP kinases."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une activation anormale des MAP kinases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes peuvent inclure inflammation, douleur et croissance cellulaire anormale."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques sont-ils liés aux MAP kinases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements des MAP kinases peuvent contribuer à des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Comment les MAP kinases affectent-elles le cancer ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activation excessive des MAP kinases peut favoriser la prolifération tumorale."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles liées aux MAP kinases ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans la signalisation des MAP kinases peuvent exacerber les maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à une inflammation chronique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rougeur, chaleur, gonflement et douleur sont des signes d'inflammation chronique."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés aux MAP kinases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine et un mode de vie actif peuvent réduire les risques associés."
}
},
{
"@type": "Question",
"name": "Les examens réguliers aident-ils à prévenir les maladies liées aux MAP kinases ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent aider à détecter précocement des anomalies."
}
},
{
"@type": "Question",
"name": "L'évitement de certains médicaments peut-il prévenir des dysfonctionnements des MAP kinases ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter certains médicaments peut réduire le risque de dysrégulation des MAP kinases."
}
},
{
"@type": "Question",
"name": "Comment le stress influence-t-il les MAP kinases ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut activer les MAP kinases, contribuant à des maladies."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles influencer la signalisation des MAP kinases ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent moduler la réponse immunitaire via les MAP kinases."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les MAP kinases dans le cancer ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques des MAP kinases, comme les inhibiteurs de MEK, sont utilisés."
}
},
{
"@type": "Question",
"name": "Les thérapies géniques peuvent-elles corriger les anomalies des MAP kinases ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie génique peut potentiellement corriger des mutations affectant les MAP kinases."
}
},
{
"@type": "Question",
"name": "Comment les anti-inflammatoires affectent-ils les MAP kinases ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anti-inflammatoires peuvent inhiber l'activation des MAP kinases, réduisant l'inflammation."
}
},
{
"@type": "Question",
"name": "Les traitements ciblés sont-ils efficaces contre les maladies liées aux MAP kinases ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements ciblés montrent des résultats prometteurs dans certaines pathologies."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des inhibiteurs de MAP kinases ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure fatigue, éruptions cutanées et troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une activation excessive des MAP kinases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent le cancer, des maladies inflammatoires et des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Les troubles cardiovasculaires sont-ils liés aux MAP kinases ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une signalisation anormale des MAP kinases peut contribuer à des troubles cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Comment les MAP kinases sont-elles impliquées dans le diabète ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les MAP kinases régulent le métabolisme du glucose, et leur dysfonction peut aggraver le diabète."
}
},
{
"@type": "Question",
"name": "Les maladies neurodégénératives sont-elles liées aux MAP kinases ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans la signalisation des MAP kinases peuvent être impliquées dans ces maladies."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'une inhibition des MAP kinases ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'inhibition peut entraîner des effets indésirables comme une immunosuppression ou des troubles de la croissance."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux troubles des MAP kinases ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs incluent des prédispositions génétiques, l'exposition à des toxines et le stress."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il les risques liés aux MAP kinases ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour les troubles des MAP kinases ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut affecter la signalisation des MAP kinases et augmenter les risques."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles influencer les MAP kinases ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent activer les MAP kinases, contribuant à des maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque pour les troubles des MAP kinases ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut altérer la signalisation des MAP kinases et augmenter le risque de cancer."
}
}
]
}
]
}
Center for Systems Biology and Molecular Medicine, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, 575018, India. keshav@yenepoya.edu.in.
Publications dans "Système de signalisation des MAP kinases" :
Proteomics and Metabolomics Core, Department of Molecular Oncology, and Department of Tumor Biology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Publications dans "Système de signalisation des MAP kinases" :
Proteomics and Metabolomics Core, Department of Molecular Oncology, and Department of Tumor Biology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Publications dans "Système de signalisation des MAP kinases" :
Proteomics and Metabolomics Core, Department of Molecular Oncology, and Department of Tumor Biology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Publications dans "Système de signalisation des MAP kinases" :
Neurobiology Laboratory, Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan. Electronic address: touqeer.ahmed@asab.nust.edu.pk.
Publications dans "Système de signalisation des MAP kinases" :
Little information is available about the clinical and pathologic characteristics of local recurrence (LR) after nipple-sparing mastectomy according to the locations of LR....
This study classified 99 patients into the following two groups according to the location of LR after nipple-sparing mastectomy: nipple-areolar recurrence (NAR) group and other locations of LR (oLR) g...
For about half of the patients (44.4 %) with NAR, the primary cancer was estrogen receptor (ER)-negative and human epidermal growth factor receptor 2 (HER2)-positive. Conversely, in most of the patien...
This multi-institutional retrospective study demonstrated that the features of NAR, such as the characteristics of the primary and recurrent tumors and the prognostic factors after LR resection, were ...
Despite advances in perioperative management, recurrence after curative pancreatectomy is a critical issue in the treatment of pancreatic ductal adenocarcinoma (PDAC). The significance of local therap...
We reviewed the medical records of patients with PDAC who underwent curative resection at our institution between January 2009 and December 2019. We examined the patterns of relapse and assessed the c...
A total of 246 patients with PDAC who underwent R0 or R1 resection were included in this study. The 3-year overall survival (OS) rate was 39.8%, and the 1-year recurrence-free survival rate was 51.2% ...
Our results suggest that a multimodal approach may improve the clinical outcomes of patients with recurrent PDAC....
Skin cancer may recur at or around the surgical site despite wide excisions. Prompt clinical and sonographic detection of local recurrence is important since subjects with relapsing melanomas or nonme...
Pathological factors that influence and predict survival following pelvic exenteration (PE) for locally advanced (LARC) or locally recurrent rectal cancer (LRRC), especially LRRC, remain poorly unders...
A retrospective cohort study was performed for all patients undergoing a curative PE for LARC or LRRC between 2008 and 2021 at a tertiary referral UK specialist colorectal hospital. Cox regression ana...
388 patients were included in the analysis with 256 resections for LARC and 132 for LRRC. 62.4% of patients were male with a median age of 59 years (IQR 49-67). 247 (64%) partial pelvic exenterations ...
A positive resection margin and poorly differentiated tumours are significant negative prognostic markers for survival and recurrence in LARC. The results of this study support the need to look for al...
Using CODA, a technique for three-dimensional reconstruction of large tissues, Kiemen et al. report observation of a microscopic focus of pancreatic cancer found in the vasculature of grossly normal h...
The initial approach to the treatment of desmoid tumors has changed from surgical resection to watchful waiting. However, surgery is still sometimes considered for some patients, and it is likely that...
We sought to explore whether a combined molecular and clinical prognostic model for relapse in patients with desmoid tumors treated with surgery would allow us to identify patients who might do well w...
This was a retrospective, single-center study of 107 patients with desmoid tumors who were surgically treated between January 1980 and December 2015, with a median follow-up of 106 months (range 7 to ...
The multivariable analysis showed that S45F mutations (hazard ratio 5.25 [95% confidence interval 2.27 to 12.15]; p < 0.001) and tumor in the extremities (HR 3.15 [95% CI 1.35 to 7.33]; p = 0.008) wer...
CTNNB1 S45F mutations combined with other clinical variables are a potential prognostic biomarker associated with the risk of relapse in patients with desmoid tumors. The developed nomogram is simple ...
Level III, therapeutic study....
A first local recurrence is common after resection or radiotherapy for brain metastasis (BM). However, patients with BMs can develop multiple local recurrences over time. Published data on second loca...
Patients were identified from a database at Brigham and Women's Hospital in Boston. Hazard ratios and 95% confidence intervals for predictors of a second local recurrence were computed using a Cox pro...
Of 170 identified surgically treated first locally recurrent lesions, 74 (43.5%) progressed to second locally recurrent lesions at a median of 7 months after craniotomy. Subtotal resection of the firs...
A second local recurrence occurred after 43.5% of craniotomies for first recurrent lesions. Subtotal resection and infratentorial location were the strongest risk factors for worse second local recurr...
The current study was undertaken to provide more detailed prognostic models for early prediction of local recurrences and local recurrence free survival (RFS) using different radiologic and pathologic...
One hundred patients with locally advanced rectal carcinomas decided to receive neoadjuvant CRT were retrospectively recruited, Hazard ratios (HR) were determined in the two cox regression models and ...
HR of 1st group of models: T+N, T+N+G, T+N+G+S, T+N+G+S+PNI, and T+N+G+S+PNI+R were summated and categorized into scores, these scores were significantly correlated with the risk of recurrence (Somer'...
We propose that the addition of biologic factors to staging of rectal cancer provide precise stratification and association with local recurrences in patients received preoperative CRT....
This study aims to identify prognostic factors and define the best extent of surgery for optimizing treatment of local recurrence (LR) following colorectal cancer (CRC)....
An institutional database of consecutive patients who underwent radical resection (R0/R1) of LR following CRC was analyzed prospectively from 2010 to 2021 at one tertiary cancer center....
In this study, 75 patients were included with LR following CRC and analyzed. Patients were categorized as compartmental resections (CompRe) (n = 47) if all adjacent organs were systematically removed,...
Complete compartmental surgery is safe and improves local control. Optimal LR resection needs to remove all contiguous organs, with or without tumor involvement....
RET-fused mesenchymal neoplasms mostly affect the soft tissue of paediatric patients. Given their responsiveness to selective RET inhibitors, it remains critical to identify those extraordinary cases ...
Clinicopathological features were assessed and partner agnostic targeted next-generation sequencing on clinically validated platforms were performed. The patients were 18, 53, and 55 years old and inc...
Our study expands the clinicopathological and genetic spectrum of mesenchymal neoplasms associated with RET fusions....
